Drug Res (Stuttg) 2018; 68(01): e1
DOI: 10.1055/a-1544-5220
Erratum

Correction: Sphingosine kinase-2 Inhibitor ABC294640 Enhances Doxorubicin-Induced Apoptosis of NSCLC Cells via Altering Survivin Expression

Leili Hasanifard
1   Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2   Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
,
Nasser Samadi
1   Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2   Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
,
Nadereh Rashtchizadeh
1   Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2   Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
,
Siavoush Dastmalchi
1   Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3   Department of Medicinal Chemistry, School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
,
Pouran Karimi
4   Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
› Institutsangaben

CORRECTION

Leili Hasanifard, Nasser Samadi, Nadereh Rashtchizadeh, Siavoush Dastmalchi, Pouran Karimi. Sphingosine kinase-2 Inhibitor ABC294640 Enhances Doxorubicin-Induced Apoptosis of NSCLC Cells via Altering Survivin Expression.

Drug Res 2018; 68: 45– 53 10.1055/s-0043-117181

In the above mention article the first names and surnames of the authors were omitted. Correct is: Leili Hasanifard, Nasser Samadi, Nadereh Rashtchizadeh, Siavoush Dastmalchi, Pouran Karimi.



Publikationsverlauf

Artikel online veröffentlicht:
26. August 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany